Clinical Study on Mannan Peptide Combined with TP Regimen for Non-small Cell Lung Cancer

It is estimated that 75% of all lung cancers, a leading cause of cancer-related death worldwide, are of non-small cell lung cancer (NSCLC) type (Qin et al., 2013; Wang et al., 2013). Most patients in China present with locally advanced stage III or IV disease. Although current practice for chemotherapy for this cohort of patients includes several newer generation agents such as vinorelbine, gemcitabine, paclitaxel or docetaxel with a platinum agent, no combination has yet emerged as a gold standard (Non-Small Cell Lung Cancer Collaborative Group, 1995; Schiller et al., 2002).Thus, cytotoxic chemotherapy, especially platinum-based doublet chemotherapy continues to be important treatment for advanced NSCLC (Lustberg et al., 2007; Obasaju et al., 2009). However, according to previous report, when oriental patients with advanced NSCLC were treated with platinum-based chemotherapy, the response rate is proximately 19%, and many of these patients would experience disease progression (Schiller et al, 2002; Yao et al, 2009; Li et al, 2011). It is hypothesized that failure of chemotherapeutic treatment could relate to , lower immunological function, multi-drug resistance (MDR) and severe toxicities that discontinue chemotherapy (Gottesman et al, 2002; Illmer et al, 2002). Mannan peptide, is a new immunological